ASCO Guidelines on adjuvant bisphosphonates in breast cancer

17 Mar 2017


Two bisphosphonates should be considered as adjuvant therapy for all postmenopausal women with early breast cancer, according to a new joint clinical practice guideline from Cancer Care Ontario and the American Society of Clinical Oncology (ASCO).

Medscape


Related Topics

Adrenal Diabetes Metabolism Obesity Cardiovascular Bone Endocrine-Disrupting Chemicals Endocrine-Related Cancer Neuroendocrinology Reproduction Steroid and Steroidogenesis Thyroid

Share this story